Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group. Miyazaki Y, et al. Among authors: horiike s. Int J Hematol. 2022 Aug;116(2):228-238. doi: 10.1007/s12185-022-03347-3. Epub 2022 May 4. Int J Hematol. 2022. PMID: 35508695 Clinical Trial.
Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study.
Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, Okumura H, Kyo T, Ueda Y, Kishimoto Y, Yagasaki F, Tsuboi K, Horiike S, Takeuchi J, Iwanaga M, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Ohno R. Jinnai I, et al. Among authors: horiike s. Int J Hematol. 2010 Oct;92(3):490-502. doi: 10.1007/s12185-010-0672-z. Epub 2010 Sep 10. Int J Hematol. 2010. PMID: 20830614 Clinical Trial.
Azacitidine-associated acute interstitial pneumonitis.
Kuroda J, Shimura Y, Mizutani S, Nagoshi H, Kiyota M, Chinen Y, Maegawa S, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. Kuroda J, et al. Among authors: horiike s. Intern Med. 2014;53(11):1165-9. doi: 10.2169/internalmedicine.53.1971. Epub 2014 Jun 1. Intern Med. 2014. PMID: 24881742 Free article.
EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.
Nishiyama D, Chinen Y, Isa R, Fujibayashi Y, Kuwahara-Ota S, Yamaguchi J, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. Nishiyama D, et al. Among authors: horiike s. Int J Hematol. 2021 Mar;113(3):381-394. doi: 10.1007/s12185-020-03027-0. Epub 2020 Oct 23. Int J Hematol. 2021. PMID: 33095415
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Matsumoto Y, Kobayashi T, Shimura Y, Kawata E, Nagoshi H, Ohshiro M, Sugitani M, Shimura K, Iwai T, Fuchida SI, Yoshida M, Kiyota M, Mizutani S, Chinen Y, Takimoto-Shimomura T, Nakao M, Kaneko H, Uchiyama H, Uoshima N, Nishigaki H, Kobayashi Y, Horiike S, Shimazaki C, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG). Matsumoto Y, et al. Among authors: horiike s. Int J Hematol. 2019 Jul;110(1):77-85. doi: 10.1007/s12185-019-02650-w. Epub 2019 May 24. Int J Hematol. 2019. PMID: 31127456 Clinical Trial.
Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka.
Kobayashi T, Kuroda J, Shimura K, Akaogi T, Kawata E, Kiyota M, Tanaka T, Kamitsuji Y, Murakami S, Hatsuse M, Okano A, Iwai T, Ueda S, Koshida M, Uchiyama H, Matsumoto Y, Kaneko H, Uoshima N, Ueda Y, Kobayashi Y, Shimazaki C, Horiike S, Taniwaki M. Kobayashi T, et al. Among authors: horiike s. Int J Hematol. 2010 Nov;92(4):579-86. doi: 10.1007/s12185-010-0696-4. Epub 2010 Oct 7. Int J Hematol. 2010. PMID: 20924731
272 results